Anti-Human EGFR Therapeutic Antibody (Panitumumab) (CAT#: TAB-020)

Recombinant monoclonal antibody to Human EGFR. Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Published Data
  • Datasheet
  • MSDS
  • COA

Figure 1 EGFR G465R mutant reveals almost complete abrogation of panitumumab and cetuximab binding.

EGFR mutation G465R abrogates binding of panitumumab and cetuximab at the protein level. Wile-type and mutant EGFR-Fc proteins were expressed and the binding of therapeutic antibodies to immobilized proteins was assessed by ELISA. Data are means from 3 experiments +/- SEM. * p<0.05, ** p<0.01, n.s. = not significant (student's T-test comparing binding of respective antibody to mutant versus wt EGFR-Fc).

Braig, F., März, M., Schieferdecker, A., Schulte, A., Voigt, M., Stein, A., ... & Engel, E. (2015). Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. Oncotarget, 6(14), 12035.

Figure 2 EGFR G465R mutant reveals almost complete abrogation of panitumumab and cetuximab binding.

Panitumumab and cetuximab binding is abrogated in CHO cells transfected with EGFR G465R . EGFR negative CHO cells were transfected with wild type EGFR or mutants thereof. Binding of panitumumab, cetuximab or a control polyclonal EGFR antibody was assessed by FACS analysis 48h after transfection. FSC = forward scatter.

Braig, F., März, M., Schieferdecker, A., Schulte, A., Voigt, M., Stein, A., ... & Engel, E. (2015). Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. Oncotarget, 6(14), 12035.

Figure 3 EGFR G465R mutation induces cross-resistance to panitumumab and cetuximab in an EGF-dependent Ba/ F3 cellular model.

A: EGFR signaling in EGF-dependent Ba/F3 model. Wt and S492R or G465R mutant EGFR-expressing Ba/F3 cells were cultured in the presence or absence of EGF and with addition of cetuximab, panitumumab, rituximab or erlotinib. After 2 hours, cells were harvested and EGFR/pEGFR expression analyzed by western blot analysis. B: Sensitivity of EGFR wt or EGFR G465R mutant- transfected Ba/F3 cells to treatment with EGFR-targeted antibodies. Ba/F3 cells were transformed to IL-3 independence with EGFR wt or mutant constructs and subsequently cultured in the presence or absence of EGF or with EGF in combination with panitumumab, cetuximab or control antibody rituximab. The number of viable cells was determined by trypan blue exclusion every 12 hours beginning 24 hours after seeding and plotted. Data are means from triplicate experiments +/-SEM.

Braig, F., März, M., Schieferdecker, A., Schulte, A., Voigt, M., Stein, A., ... & Engel, E. (2015). Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. Oncotarget, 6(14), 12035.

Figure 4 In vitro EGFR targeting of panitumumab.

Immunofluorescence staining of UM-SCC-22B tumor cells and tissues for EGFR using panitumumab as the primary antibody.

Liu, Z., Liu, Y., Jia, B., Zhao, H., Jin, X., Li, F., ... & Wang, F. (2010). Epidermal growth factor receptor–targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab. Molecular cancer therapeutics, 1535-7163.

Figure 5 In vitro EGFR targeting of panitumumab.

In vitro inhibition of 125I-panitumumab binding to EGFR on UM-SCC-22B human head and neck cancer cells by DOTA-panitumumab and panitumumab. Points, mean (n = 3); bars, SD.

Liu, Z., Liu, Y., Jia, B., Zhao, H., Jin, X., Li, F., ... & Wang, F. (2010). Epidermal growth factor receptor–targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab. Molecular cancer therapeutics, 1535-7163.


Specifications

  • Immunogen
  • EGFR expressed on the surface of cells (A431 cells)
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • IgG2 - kappa
  • Specificity
  • Tested positive against native human antigen
  • Species Reactivity
  • Human
  • Applications
  • ELISA, IP, FC, FuncS, Neut, IF, ICC
  • Trade name
  • vectibix
  • CAS
  • 339177-26-3
  • Generic Name
  • Panitumumab
  • Biological Half-Life
  • 9.4 days (range: 4-11 days)
  • ATC Code
  • L01XC08
  • DrugBank
  • DB01269
  • UNII
  • 6A901E312A
  • ChEMBL
  • CHEMBL1201827
  • MW
  • 144,324.12 g/mol
  • Related Disease
  • Colorectal cancers

Applications

  • Application Notes
  • The EGFR antibody has been reported in applications of ELISA, FC, WB, IF, Inhib.
    IF: UM-SCC-22B cell staining study was done as previously described with some modifications (17). Briefly, 70% to 85% confluent tumor cells grown in 35-mm MatTek glass-bottomed culture dishes were fixed using 4% paraformaldehyde for 10 minutes. After blocking with 10% FBS in PBS for 30 minutes, the cells were incubated with panitumumab (5 μg/mL) for 1 hour. The cells were then washed with PBS and stained with FITC-coupled mouse anti–human IgG (hIgG) for 30 minutes. After the final wash with PBS, the cells were visualized using a Leica TCS-NT confocal microscope (Wetzler).

Target

  • Alternative Names
  • Panitumumab;vectibix;339177-26-3;ABX-EGF;ABX-EGF;Vectibix;DB01269EGFR;epidermal growth factor receptor;epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog) , ERBB;ERBB1;erythroblastic leukemia viral (v erb b) o

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Resources

Please click here for more details about the introduction to mechanism of action, clinical projects and approved drugs of Panitumumab.

See other products for "Panitumumab"

Afuco™ Anti-EGFR ADCC Therapeutic Antibody (Panitumumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human EGFR. Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).

See other products for "EGFR"

* Abbreviations
3D IHC3D Immunohistochemistry
ActivActivation
AgonistAgonist
ApopApoptosis
BABioassay
BIBioimaging
BlockBlocking
Cell ScreeningCell Screening
SeparationCell Separation
ChIPChromatin Immunoprecipitation
CMCDComplement Mediated Cell Depletion
CostimCostimulation
CytCytotoxicity
DepletionDepletion
DBDot Blot
EMElectron Microscopy
ELISAEnzyme-linked Immunosorbent Assay
ELISPOTEnzyme-linked Immunosorbent Spot
FCFlow Cytometry
FuncSFunctional Assay
GSGel Super Shift Assay
HAHemagglutination
IAImmunoassay
IBImmunoblotting
ICCImmunocytochemistry
IDImmunodiffusion
IFImmunofluorescence
IHCImmunohistochemistry
IHC-FrImmunohistochemistry-Frozen
IHC-PImmunohistochemistry-Paraffin
REImmunohistology - Resin Sections
IPImmunoprecipitation
IRMAImmunoradiometric Assay
SHIn situ hybridization
InhibInhibition
ICFCIntracellular Staining for Flow Cytometry
KO/KD-WBKnockout/Knockdown target confirmation by Western Blot
Live cell imagingLive cell imaging
CyTOF®Mass Cytometry
MeDIPMethylated DNA Immunoprecipitation
MultiplexMultiplex bead-based assay
NeutNeutralization
PPProtein Purification
PGProteogenomics
RIRadial Immunodiffusion
RIARadioimmunoassay
StimStimulation
SPRSurface Plasmon Resonance
TCTissue Culture
TBTurbidimetry
WBWestern Blot

Send Inquiry

  • Verification code
    Click image to refresh the verification code.
© 2007 - 2020 Creative BioLabs All Rights Reserved
  • 0
  • 0

Cart